Private equity firm Bridgepoint has acquired a majority stake in GBA, a major German diagnostics and laboratory chain.
The transaction marks a significant shift in ownership for the healthcare services provider, which remains under private equity control after years of operation under its previous owner, Ardian.
The deal underscores the continued appetite for healthcare infrastructure assets among institutional investors.
GBA operates as a key competitor to Synlab, one of Europe's largest laboratory networks.
The acquisition suggests Bridgepoint sees value in consolidating or expanding its position in the fragmented European diagnostics market, where scale and network density are critical competitive advantages.
According to reports from FAZ and FT, the transaction is valued in the billions, reflecting the premium placed on stable cash flows and essential healthcare services.